News

Pfizer Inc. and BioNTech SE announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts...

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,  announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for provisional registration of NVX-CoV2373, Novavax' COVID-19 vaccine (adjuvanted), for active immunization to...

Bristol-Myers Squibb announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R)...

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and...

Ashfield Engage, part of UDG Healthcare, has announced the acquisition of Medaxis, a patient engagement services partner for the life sciences industry, providing services to healthcare professionals and patients. Ashfield Engage, which has a Patient Solutions offering specializing in patient...

Fermenta Biotech Limited  announced that it has signed a Definitive Agreement with Aurigene Pharmaceutical Services Limited (APSL), a stepdown subsidiary of Dr Reddy’s Laboratories Limited (DRL). In this arrangement, FBL will exclusively license its proprietary biocatalytic technology for synthesis...

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, GMP vector production and analytical testing services, has appointed Laura Jacanin as Senior Director of Business Development. Previously with similar roles at Wuxi,...